Skip to main content
OpenTrials
Completed

NCT Number: NCT05372900

Nutritional Intervention to Improve Sleep Quality and Improve Next-day Mood and Cognitive Benefits

The study aim to test the effect of a meal complement to be taken in combination with an evening meal with a glycemic load of 55, to improve sleep quality.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

25 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre for Sleep and Cognition, NUS Yong Loo Lin School of Medicine

Singapore, 117549

About this study

Considering emerging evidence on the role of the macro and micro-nutrient composition of evening meals, the intervention used in this study will be designed to provide the necessary nutrients to promote sleep quality. The IP will be a low caloric nutritional solution, combining:

  • Ingredients lowering glycemic response to evening meals to promote sleep quality
  • a protein source rich in bioavailable tryptophan to promote sleep quality
  • supporting ingredients contributing to sleep initiation

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able provide written informed consent (in English)
  • Aged 25-50
  • BMI range from 18.5 to 24.9 kg/m2
  • Subjective sleep complaints (PSQI > 5)

Exclusion criteria

  • Diagnosed food allergy or other intolerance to the investigational products, control products and standardized meals
  • Significant past medical and psychiatric history and ongoing chronic conditions for example cardiovascular disease, respiratory disease, metabolic disorder, endocrine disorder (e.g. diabetes mellitus, history of hypoglycemia), and neurological and psychiatric conditions, and conditions that the investigator deem inappropriate to enter the clinical trials
  • Significant medication history including use of corticosteroid in oral or systemic format and antidepressants (e.g. Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors)
  • Pregnant or intending to conceive during the course of clinical trial and up to one month after trial conclusion, or not able to comply with a highly effective form of birth control or lactating during the clinical trial. Highly effective contraception includes hormonal methods, such as the contraceptive pill or implant, or an intrauterine device (IUD), or barrier methods such as diaphragm plus spermicide or condom plus spermicide. Pregnancy status will be assessed using urinary dipsticks at the beginning and end of the study period (V0 and V9).
  • Parents of children less than 12 months of age, which is a known factor of sleep disturbances.
  • Peri- and post-menopausal women
  • Known or diagnosed sleep disorders
  • Special diets, including for instance halal food preference, vegetarian, high protein or weight loss program, and diets with either too low (< 35% daily energy from CHO; e.g., ketogenic diet, Atkins diet, zero-carb diet, low-carb paleo/Mediterranean diet, carb cycling diet) or too high carbohydrate (>70% daily energy from CHO) content .
  • Chronic exercisers, defined as subjects exercising > 1 h/day for at least 5 days/week
  • Caffeine consumption over the recommended daily limit (above 400 mg; equivalent to approximately 4-5 cups of coffee)
  • Substance abuse including over the limit alcohol consumption (2 standard drinks/day for males, 1 standard drink/day for female)
  • Cigarette and Tobacco Smokers
  • Intake of dietary supplements that may affect sleep conditions (e.g. melatonin, theanine, tryptophan, GABA, magnesium, zinc)
  • Subjects not willing and/or not able to comply with scheduled visits and the requirements of the study protocol.
  • Participating in other clinical trials or had been participating in other clinical trial in the preceding 1 month.
  • Subjects belonging to a household where at least one other person is taking part in the trial.

Treatment and study plan

Test Product

Other

Whey Protein Isolate with Mulberry leaf extract

Control product

Other

Wheat Protein Hydrolysate

Primary outcomes

  1. Changes in sleep efficiency (actigraphy)

    Time frame: Day 1 (V1) to Day 15 (V2), Day 22 (V3) to Day 37, Day 38 (V5) to Day 45, Day 59 (V6) to Day 65, Day 66 (V7) to Day 79, Day 80 (V8) to Day 87 (V9)

    Calculated as '(total time asleep / time in bed) X 100; sleep efficiency above 85% is considered good.

  2. Change in sleep latency (actigraphy)

    Time frame: Day 1 (V1) to Day 15 (V2), Day 22 (V3) to Day 37, Day 38 (V5) to Day 45, Day 59 (V6) to Day 65, Day 66 (V7) to Day 79, Day 80 (V8) to Day 87 (V9)

    Measured as the amount of time it takes subjects to fall asleep after going to bed (in minutes)

Secondary outcomes

  1. Changes in self-reported sleep quality via Actigraphy

    Time frame: Day 1 (V1) to Day 15 (V2) , Day 22 (V3) to Day 37, Day 38 (V5) to Day 45, Day 59 (V6) to Day 65, Day 66 (V7) to Day 79, Day 80 (V8) to Day 87 (V9)

    Changes in WASO & total sleep duration

  2. Changes in self-reported sleep quality via KSD

    Time frame: Day 1 (V1), Day 15 (V2), Day 22 (V3), Day 23, Day 24 (V4) to Day 37, Day 45 and 65, Day 66 (V7) to Day 79, Day 87 (V9)

    Changes in self-reported sleep quality measured through questionnaire Karolinska Sleep Diary (KSD)

  3. Changes in self-reported sleep quality via ESS

    Time frame: Day 1 (V1) & Day 15 (V2), Day 23, 31, 37, 45, 65, 73, 79, 87)

    Changes in self-reported sleep quality measured through questionnaire Epworth Sleepiness Scale (ESS)

  4. Glycemia

    Time frame: Day 1 (V1) to Day 14, Day 24 (V4) to Day 37, Day 66 (V7) 7 to Day 79

    Glycemia measured by continuous glucose monitoring:

    • Glucose response of the evening standard meal with the test product or the control product
    • Glucose excursion during the night (from time to bed to wakening)
    • Subsequent breakfast
  5. Mood states, alertness, and sleepiness via BMIS

    Time frame: Day 22 (V3), Day 23 to Day 37, Day 65, Day 66 (V7) to Day 79

    Questionnaire Brief Mood Introspection Scale (BMIS)

  6. Mood states, alertness, and sleepiness via KSS

    Time frame: Day 22 (V3), Day 23 to Day 37, Day 65, Day 66 (V7) to Day 79

    Questionnaire Karolinska Sleepiness Scale (KSS)

  7. Mood states, alertness, and sleepiness via POMS-SF 2

    Time frame: Day 22 (V3), Day 23, 31, 37, 65, 73, 79

    Questionnaire Profile of Mood States - Short Form 2 (POMS-SF 2)

  8. Cognition tasks via Immediate & delayed free recall

    Time frame: Day 22 (V3), Day 23, 37, 65, 79

    Immediate & delayed free recall

  9. Cognition task PVT

    Time frame: Day 22 (V3), Day 23, 31, 37, 65, 73, 79

    Psychomotor Vigilance Task (PVT)

  10. Cognition test N-back task

    Time frame: Day 22 (V3), Day 23, 31, 37, 65, 73, 79

    N-back task

  11. Cognition test Go/No-Go task

    Time frame: Day 22 (V3), Day 23, 31, 37, 65, 73, 79

    Go/No-Go task

  12. Cognition task NASA-TLX

    Time frame: Day 22 (V3), Day 23, 31, 37, 65, 73, 79

    NASA task load index (NASA-TLX)

Other outcomes

  1. Cortisol levels in the morning

    Time frame: Day 24 (V4), Day 28 (V5), Day 66 (V7), Day 80 (V8)

    Cortisol levels in saliva as an objective index of stress

  2. Melatonin synthesis marker (6-sulfatoxymelatonin)

    Time frame: Day 24 (V4), Day 28 (V5), Day 66 (V7), Day 80 (V8)

    6-sulfatoxymelatonin levels in urine as an index of melatonin synthesis, which will be reported as a ratio of urinary 6-sulfatoxymelatonin to urinary creatinine.

  3. Assess effect of sleep hygiene behaviors and life events on sleep patterns

    Time frame: Visit 0 (pre Day1), Day 23, Day 65

    Sleep hygiene questionnaire

  4. Change in sleep efficiency, calculated as '(total time asleep / time in bed) X 100; sleep efficiency above 85% is considered good

    Time frame: Day 1 (V1) to Day 15 (V2), Day 22 (V3) to Day 37, Day 38 (V5) to Day 45, Day 59 (V6) to Day 65, Day 66 (V7) to Day 79, Day 80 (V8) to Day 87 (V9)

    Measure of sleep parameter using the commercial sensor Oura ring

  5. Change in sleep latency (mins), measured in time needed to fall asleep after going to bed.

    Time frame: Day 1 (V1) to Day 15 (V2), Day 22 (V3) to Day 37, Day 38 (V5) to Day 45, Day 59 (V6) to Day 65, Day 66 (V7) to Day 79, Day 80 (V8) to Day 87 (V9)

    Measure of sleep parameter using the commercial sensor Oura ring

  6. Change in WASO (actigraphy) - proportion of people reaching < 30 mins

    Time frame: Day 1 (V1) to Day 15 (V2), Day 22 (V3) to Day 37, Day 38 (V5) to Day 45, Day 59 (V6) to Day 65, Day 66 (V7) to Day 79, Day 80 (V8) to Day 87 (V9)

    Measure of sleep parameter using the commercial sensor Oura ring

  7. Change in total sleep duration (mins; actigraphy)

    Time frame: Day 1 (V1) to Day 15 (V2), Day 22 (V3) to Day 37, Day 38 (V5) to Day 45, Day 59 (V6) to Day 65, Day 66 (V7) to Day 79, Day 80 (V8) to Day 87 (V9)

    Measure of sleep parameter using the commercial sensor Oura ring.

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
May 13, 2022
Registry last updated
Jul 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.